By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.
The board had previously approved a $100 million stock buyback program in March.
Registering provides access to this and other free content.
Already have an account?Login Now.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.